Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario'

Comments
Loading...
  • Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc ABEO from $22 to $40 after adjusting the market model/ increasing the probability of success for EB-101.
  • Last week, the company reported topline data from the pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). 
  • The study met its two co-primary efficacy endpoints demonstrating statistically significant, clinically meaningful improvements in wound healing and pain reduction in large chronic RDEB wounds.
  • The analyst increased the probability of success from 70% to 85% to reflect the positive data and believes the data supporting EB-101 to become the standard of care for RDEB.
  • Cantor emphasizes its belief Abeona is the only company to now show positive pivotal data in RDEB when evaluating the larger, chronic wounds.
  • The positive data and capital raise of $35 million remove a financial overhang on the company, and investors can focus on the next step of potential commercialization, the analyst writes.
  • Price Action: ABEO shares are down 0.41% at $3.655 on the last check Tuesday.
  • Photo Via Company
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!